Jefferies Starts Roivant Sciences (ROIV) at Buy

October 26, 2021 7:38 AM EDT
Get Alerts ROIV Hot Sheet
Price: $3.95 +1.02%

Rating Summary:
    7 Buy, 1 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 10 | Down: 13 | New: 20
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Jefferies analyst Dennis Ding initiates coverage on Roivant Sciences (NASDAQ: ROIV) with a Buy rating and a price target of $10.00.

The analyst commented, "ROIV is a diversified healthcare company employing a novel hub-and-spoke model, which enables its 10+ subsidiaries (Vants) substantial flexibility in maximizing shareholder returns. ROIV's Vants already have many drugs in the clinic including one already under review by the FDA, but we expect derisking of add'l drugs over the next 1-2+ years plus cont'd capital deployment in novel areas to create significant long-term value too - Initiate at Buy with a $10 PT."

For an analyst ratings summary and ratings history on Roivant Sciences click here. For more ratings news on Roivant Sciences click here.

Shares of Roivant Sciences closed at $7.04 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co, FDA